Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipher Pharmaceuticals Inc.

www.cipherpharma.com

Latest From Cipher Pharmaceuticals Inc.

Sun Sees Urgency To Establish Low Dose Absorica In US

Sun’s key specialty asset Ilumya makes progress, albeit slowly, in the US, while the firm sees ‘short window’ to ensure that Absorica LD gains grip in that market ahead of impending arrival of generic.

Commercial Sales & Earnings

Deal Watch, Licensing Focus: Roche, Sanofi Exit Ongoing Anticalin Development Efforts With Pieris

Sarepta licenses gene therapy candidate from Lacerta, also makes equity investment. Neuren licenses North American rights to rare disease drug trofinetide to Acadia.

Deals Business Strategies

Start-Up Quarterly Statistics: Financings Finally Rise In Q1, But Deals Stagnate

Biopharma start-ups finally had an increase in financing activity, following three sequential quarters with a decrease. A review of biopharma start-up dealmaking and financing activity from January through March 2018, based on data from Strategic Transactions.

Deals Financing

Deal Watch: Roivant Adds Ligand's Glucose Receptor Antagonist To Metavant Pipeline

Celgene will pursue "high-impact" indications using Vividion's proteomics technology, while Magenta will use Heidelberg's technology to try to optimize bone marrow transplants.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Dermatology
  • Gastrointestinal
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Cipher Pharmaceuticals Inc.
  • Senior Management
  • Craig Mull, Interim CEO
    Diane Gajewczyk, VP, Scientific & Medical Affairs
  • Contact Info
  • Cipher Pharmaceuticals Inc.
    Phone: (905) 602-5840
    209 Oak Park Blvd., Ste. 501
    Oakville, L6H 0M2
    Canada
UsernamePublicRestriction

Register